Sucampo Pharmaceuticals (SCMP) 6.80 $SCMP
Why Sucampo Pharmaceuticals, Inc. Shares Temporarily Dropped
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 1:19PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sucampo Pharmaceuticals , a biotechnology...
Sucampo Pharmaceuticals, Inc., Reports First Quarter 2014 Financial and Operating Results
GlobeNewswire - Wed May 07, 3:47PM CDT
Strong Financial Performance Driven by Year over Year Income and Revenue Growth
Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Journal
GlobeNewswire - Tue May 06, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, announced that its recent study, "A Randomized Study of Lubiprostone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain," has been published online in the medical journal, Pain Medicine. The study examines the efficacy and safety of AMITIZA (oral lubiprostone) for relieving symptoms of opioid-induced constipation (OIC) in chronic non-cancer pain.
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences
GlobeNewswire - Thu May 01, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. ("Sucampo"
(Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be presented at the American Pain Society ("APS" Conference in Tampa, Florida and Digestive Disease Week ("DDW" 2014 in Chicago, Illinois. The information regarding both presentations can be found below.
Sucampo Pharmaceuticals Announces First Quarter 2014 Results and Operating Highlights Teleconference and Webcast
GlobeNewswire - Wed Apr 30, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo" , a global biopharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the first quarter ended March 31, 2014, on Wednesday, May 7, 2014, at 5:00 pm Eastern. The press release announcing the financial results and operating highlights is expected to be released after the close of the capital markets that day.
Cytokinetics' Tirasemtiv Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 2:22PM CDT
Shares of Cytokinetics tumbled 64.7% after it announced that tirasemtiv failed to meet its primary endpoint in the phase IIb, BENEFIT-ALS study.
Global Opioid Induced Bowel Dysfunction Clinical Trials Review 2014 Featuring the Top 9 Companies/Institutes in the Field
M2 - Mon Apr 28, 5:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxs8hs/opioid_induced) has announced the addition of the "Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014" report to their offering. Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014" provides data on the Opioid Induced Bowel Dysfunction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid Induced Bowel Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid Induced Bowel Dysfunction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies & Institutes - GlaxoSmithKline plc - Cubist Pharmaceuticals, Inc. - Salix Pharmaceuticals Ltd. - Sucampo Pharmaceuticals, Inc. - Shionogi & Co., Ltd. - Helsinn Holding S.A. - Yokohama City University Hospital - Mech-Sense - Kuopio University Hospital For more information visit http://www.researchandmarkets.com/research/qx...id_induced
Global Oral Mucositis Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9vr8h/oral_mucositis) has announced the addition of the "Global Oral Mucositis Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Oral Mucositis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Oral Mucositis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Daewoong Pharmaceutical Co., Ltd. - Soligenix, Inc. - BioAlliance Pharma SA - Sucampo Pharmaceuticals, Inc. - ActogeniX NV - Alder Biopharmaceuticals Inc. - Promedior, Inc. - ProCertus BioPharm Inc. - GliaMed, Inc. - Avaxia Biologics, Inc. - Cellceutix Corporation - Vicus Therapeutics, LLC - Nephrx Corporation - Laila Pharmaceuticals Pvt. Ltd. - Applied Protein Sciences, LLC Drug Profiles - nepidermin - Lactobacillus CD2 Lozenges - sucralfate - clonidine hydrochloride ER - clazakizumab - SGX-942 - LP-004-09 - methionine - Quercetin - selenium sulfide - AG-013 - cobiprostone - GC-4403 - GM-1485 - brilacidin - PRM-151 - NX-002 - Hybrid Adenoretroviral Vectors - Regenasyn - GC-4419 - AP-002 - AP-001 - OralX - (captopril teprenone) - Anti-TNF Antibody For Oral Mucositis For more information visit http://www.researchandmarkets.com/research/l9..._mucositis
Preclinical Data for Lubiprostone and Unoprostone Isopropyl to be Presented at Experimental Biology Conference 2014
GlobeNewswire - Fri Apr 25, 3:09PM CDT
Sucampo Pharmaceuticals, Inc. ("Sucampo" (Nasdaq:SCMP), a global biopharmaceutical company, today announced that preclinical data for lubiprostone and unoprostone isopropyl will be presented at the Experimental Biology Society 2014 Conference in San Diego, California.
OncoGenex Gains Fast Track Status for Custirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:50PM CDT
FDA granted Fast Track status to OncoGenex Pharmaceuticals, Inc.'s (OGXI) oncology candidate, custirsen
Epizyme Up on Milestone Payment from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 6:10PM CDT
Shares of Epizyme (EPZM) were up 8.3% after the company announced the achievement of one of the HMT targets.
Global Opioid-Induced Constipation (OIC) Therapeutics Pipeline Review 2014 - Analysis of 11 Companes & 13 Drug Profiles
M2 - Wed Apr 23, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3fs6f/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Cubist Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Theravance, Inc. - Sucampo Pharmaceuticals, Inc. - AIKO Biotechnology, Inc. - Synergy Pharmaceuticals, Inc. - S.L.A. Pharma AG - Develco Pharma Schweiz AG Drug Profiles - naloxegol - lubiprostone - methylnaltrexone bromide - methylnaltrexone bromide - naldemedine - bevenopran - naloxone hydrochloride PR - methylnaltrexone bromide - TD-1211 - naloxone hydrochloride SR - SP-333 - naloxone hydrochloride - (6-beta-naltrexol oxycodone) For more information visit http://www.researchandmarkets.com/research/l3...oidinduced
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 3:10PM CDT
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.
Tech Council of Maryland Names New Board Members
Business Wire - Thu Mar 27, 7:00AM CDT
The Tech Council of Maryland (TCM), Maryland's largest technology trade association for life science and technology, today announced that individuals from IBM, Sucampo Pharmaceuticals and the Universities at Shady Grove (USG) were named to the board of directors.
VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer
PR Newswire - Tue Mar 25, 7:38AM CDT
VLP Therapeutics, Inc. ("VLP" , a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i-aVLP technology (which stands for "inserted alpha virus like particle" , today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) ("Sucampo" will join VLP as Chair and Chief Medical Officer, effective today.
Sucampo Co-Founder and Chairman Emeritus, Dr. Ryuji Ueno, to Receive Visionary Award From the Foundation Fighting Blindness
GlobeNewswire - Tue Mar 25, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the Foundation Fighting Blindness (Foundation), a national nonprofit driving sight-saving research, will honor Sucampo's Co-Founder and Chairman Emeritus, Ryuji Ueno, M.D., Ph.D., Ph.D., with the Foundation's Visionary Award, in recognition of Dr. Ueno's longstanding commitment to helping patients with eye diseases. The 12th Annual D.C. "For the Love of Sight" Visionary Awards Dinner will take place on Tuesday, April 1, at 6 p.m. Eastern, at the Ritz-Carlton - Downtown, Washington, D.C., to benefit research into preventions, treatments and cures for vision-robbing retinal diseases including macular degeneration, retinitis pigmentosa (RP), Usher syndrome and related conditions that affect more than 10 million Americans.
Sucampo's NDA Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:05PM CDT
Sucampo Pharma recently announced that its New Drug Application (NDA) for the liquid formulation of Amitiza will not be filed in the second half of 2014.
Why Sucampo Pharmaceuticals, Inc. Shares Temporarily Dropped
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 1:19PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sucampo Pharmaceuticals , a biotechnology...
Sucampo Pharmaceuticals, Inc., Reports First Quarter 2014 Financial and Operating Results
GlobeNewswire - Wed May 07, 3:47PM CDT
Strong Financial Performance Driven by Year over Year Income and Revenue Growth
Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Journal
GlobeNewswire - Tue May 06, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, announced that its recent study, "A Randomized Study of Lubiprostone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain," has been published online in the medical journal, Pain Medicine. The study examines the efficacy and safety of AMITIZA (oral lubiprostone) for relieving symptoms of opioid-induced constipation (OIC) in chronic non-cancer pain.
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences
GlobeNewswire - Thu May 01, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. ("Sucampo"
(Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be presented at the American Pain Society ("APS" Conference in Tampa, Florida and Digestive Disease Week ("DDW" 2014 in Chicago, Illinois. The information regarding both presentations can be found below. Sucampo Pharmaceuticals Announces First Quarter 2014 Results and Operating Highlights Teleconference and Webcast
GlobeNewswire - Wed Apr 30, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"
, a global biopharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the first quarter ended March 31, 2014, on Wednesday, May 7, 2014, at 5:00 pm Eastern. The press release announcing the financial results and operating highlights is expected to be released after the close of the capital markets that day. Cytokinetics' Tirasemtiv Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 2:22PM CDT
Shares of Cytokinetics tumbled 64.7% after it announced that tirasemtiv failed to meet its primary endpoint in the phase IIb, BENEFIT-ALS study.
Global Opioid Induced Bowel Dysfunction Clinical Trials Review 2014 Featuring the Top 9 Companies/Institutes in the Field
M2 - Mon Apr 28, 5:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxs8hs/opioid_induced) has announced the addition of the "Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014" report to their offering. Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014" provides data on the Opioid Induced Bowel Dysfunction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid Induced Bowel Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid Induced Bowel Dysfunction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies & Institutes - GlaxoSmithKline plc - Cubist Pharmaceuticals, Inc. - Salix Pharmaceuticals Ltd. - Sucampo Pharmaceuticals, Inc. - Shionogi & Co., Ltd. - Helsinn Holding S.A. - Yokohama City University Hospital - Mech-Sense - Kuopio University Hospital For more information visit http://www.researchandmarkets.com/research/qx...id_induced
Global Oral Mucositis Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9vr8h/oral_mucositis) has announced the addition of the "Global Oral Mucositis Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Oral Mucositis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Oral Mucositis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Daewoong Pharmaceutical Co., Ltd. - Soligenix, Inc. - BioAlliance Pharma SA - Sucampo Pharmaceuticals, Inc. - ActogeniX NV - Alder Biopharmaceuticals Inc. - Promedior, Inc. - ProCertus BioPharm Inc. - GliaMed, Inc. - Avaxia Biologics, Inc. - Cellceutix Corporation - Vicus Therapeutics, LLC - Nephrx Corporation - Laila Pharmaceuticals Pvt. Ltd. - Applied Protein Sciences, LLC Drug Profiles - nepidermin - Lactobacillus CD2 Lozenges - sucralfate - clonidine hydrochloride ER - clazakizumab - SGX-942 - LP-004-09 - methionine - Quercetin - selenium sulfide - AG-013 - cobiprostone - GC-4403 - GM-1485 - brilacidin - PRM-151 - NX-002 - Hybrid Adenoretroviral Vectors - Regenasyn - GC-4419 - AP-002 - AP-001 - OralX - (captopril teprenone) - Anti-TNF Antibody For Oral Mucositis For more information visit http://www.researchandmarkets.com/research/l9..._mucositis
Preclinical Data for Lubiprostone and Unoprostone Isopropyl to be Presented at Experimental Biology Conference 2014
GlobeNewswire - Fri Apr 25, 3:09PM CDT
Sucampo Pharmaceuticals, Inc. ("Sucampo"
(Nasdaq:SCMP), a global biopharmaceutical company, today announced that preclinical data for lubiprostone and unoprostone isopropyl will be presented at the Experimental Biology Society 2014 Conference in San Diego, California. OncoGenex Gains Fast Track Status for Custirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:50PM CDT
FDA granted Fast Track status to OncoGenex Pharmaceuticals, Inc.'s (OGXI) oncology candidate, custirsen
Epizyme Up on Milestone Payment from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 6:10PM CDT
Shares of Epizyme (EPZM) were up 8.3% after the company announced the achievement of one of the HMT targets.
Global Opioid-Induced Constipation (OIC) Therapeutics Pipeline Review 2014 - Analysis of 11 Companes & 13 Drug Profiles
M2 - Wed Apr 23, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3fs6f/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Cubist Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Theravance, Inc. - Sucampo Pharmaceuticals, Inc. - AIKO Biotechnology, Inc. - Synergy Pharmaceuticals, Inc. - S.L.A. Pharma AG - Develco Pharma Schweiz AG Drug Profiles - naloxegol - lubiprostone - methylnaltrexone bromide - methylnaltrexone bromide - naldemedine - bevenopran - naloxone hydrochloride PR - methylnaltrexone bromide - TD-1211 - naloxone hydrochloride SR - SP-333 - naloxone hydrochloride - (6-beta-naltrexol oxycodone) For more information visit http://www.researchandmarkets.com/research/l3...oidinduced
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 3:10PM CDT
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.
Tech Council of Maryland Names New Board Members
Business Wire - Thu Mar 27, 7:00AM CDT
The Tech Council of Maryland (TCM), Maryland's largest technology trade association for life science and technology, today announced that individuals from IBM, Sucampo Pharmaceuticals and the Universities at Shady Grove (USG) were named to the board of directors.
VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer
PR Newswire - Tue Mar 25, 7:38AM CDT
VLP Therapeutics, Inc. ("VLP"
, a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i-aVLP technology (which stands for "inserted alpha virus like particle" , today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) ("Sucampo" will join VLP as Chair and Chief Medical Officer, effective today. Sucampo Co-Founder and Chairman Emeritus, Dr. Ryuji Ueno, to Receive Visionary Award From the Foundation Fighting Blindness
GlobeNewswire - Tue Mar 25, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the Foundation Fighting Blindness (Foundation), a national nonprofit driving sight-saving research, will honor Sucampo's Co-Founder and Chairman Emeritus, Ryuji Ueno, M.D., Ph.D., Ph.D., with the Foundation's Visionary Award, in recognition of Dr. Ueno's longstanding commitment to helping patients with eye diseases. The 12th Annual D.C. "For the Love of Sight" Visionary Awards Dinner will take place on Tuesday, April 1, at 6 p.m. Eastern, at the Ritz-Carlton - Downtown, Washington, D.C., to benefit research into preventions, treatments and cures for vision-robbing retinal diseases including macular degeneration, retinitis pigmentosa (RP), Usher syndrome and related conditions that affect more than 10 million Americans.
Sucampo's NDA Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:05PM CDT
Sucampo Pharma recently announced that its New Drug Application (NDA) for the liquid formulation of Amitiza will not be filed in the second half of 2014.
